Jacob Gadwa

Jacob Gadwa

Auto-generated profile, based on publicly available information

Jacob Gadwa

University of Colorado Denver 1 Department of Radiation Oncology Anschutz Medical Campus, Aurora, Colorado

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2021 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
MKMichael W Knitz
Michael W Knitz
TBThomas Bickett
Thomas Bickett
LDLaurel B Darragh
Laurel B Darragh
Ayman OweidaAyman Oweida
Ayman Oweida
SBShilpa Bhatia
Shilpa Bhatia
SKSana D. Karam
Sana D. Karam
Background: Numerous trials combining radiation therapy (RT) and immunotherapy in head and neck squamous cell carcinoma (HNSCC) are failing. Using preclinical immune cold models of HNSCC resistant to RT-immune checkpoint inhibitors, we investigate therapeutic approaches of overcoming such resistance by examining the differential microenvironmental response to RT. Methods: We subjected two HPV-negative orthotopic mouse models of HNSCC to combination RT, regulatory T cells (Treg) depletion, and/or CD137 agonism. Tumor growth was measured and intratumorous and lymph node immune populations were compared among treatment groups. Human gene sets, genetically engineered mouse models DEREG and BATF3–/–, flow and time-of-flight cytometry, RNA-Seq, Treg adoptive transfer studies, and in vitro experiments were used to further evaluate the role of dendritic cells (DCs) and Tregs in these treatments. Results: In MOC2 orthotopic tumors, we find no therapeutic benefit to targeting classically defined immunosuppressive myeloids, which increase with RT. In these radioresistant tumors, supplementing combination RT and Treg depletion with anti-CD137 agonism stimulates CD103+ DC activation in tumor-draining lymph nodes as characterized by increases in CD80+ and CCR7+ DCs, resulting in a CD8 T cell-dependent response. Simultaneously, Tregs are reprogrammed to an effector phenotype demonstrated by increases in interferonγ+, tumor necrosis factorα+, PI3K+, pAKT+ and Eomes+ populations as well as decreases in CTLA4+ and NRP-1+ populations. Tumor eradication is observed when RT is increased to an 8 Gy x 5 hypofractionated regimen and combined with anti-CD25+ anti-CD137 treatment. In a human gene set from oral squamous cell carcinoma tumors, high Treg number is associated with earlier recurrence. Conclusions: Regulating Treg functionality and DC activation status within the lymph node is critical for generating a T cell effector response in these highly radioresistant tumors. These findings underscore the plasticity of Tregs and represent a new therapeutic opportunity for reprogramming the tumor microenvironment in HNSCCs resistant to conventional radioimmunotherapy approaches.

31 March 2021 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
JGJacob Gadwa
Jacob Gadwa
TBThomas E Bickett
Thomas E Bickett
LDLaurel B Darragh
Laurel B Darragh
MKMichael William Knitz
Michael William Knitz
SBShilpa Bhatia
Shilpa Bhatia
SKSana D. Karam
Sana D. Karam
Background: Resistance to therapy is a major problem in treating head and neck squamous cell carcinomas (HNSCC). Complement system inhibition has been shown to reduce tumor growth, metastasis, and therapeutic resistance in other tumor models, but has yet to be explored in the context of HNSCC. Here, we tested the effects of complement inhibition and its therapeutic potential in HNSCC. Methods: We conducted our studies using two Human Papilloma Virus (HPV)-negative HNSCC orthotopic mouse models. Complement C3aR and C5aR1 receptor antagonists were paired with radiation therapy (RT). Tumor growth was measured and immune populations from tumor, lymph node, and peripheral blood were compared among various treatment groups. Genetically engineered mouse models DEREG and C3-/- were used in addition to standard wild type models. Flow cytometry, clinical gene sets, and in vitro assays were used to evaluate the role complement receptor blockade has on the immunological makeup of the tumor microenvironment. Results: In contrast to established literature, inhibition of complement C3a and C5a signaling using receptor antagonists accelerated tumor growth in multiple HNSCC cell lines and corresponded with increased frequency of regulatory T cell (Treg) populations. Local C3a and C5a signaling has importance for CD4 T cell homeostasis and eventual development into effector phenotypes. Interruption of this signaling axis drives a phenotypic conversion of CD4+ T cells into Tregs, characterized by enhanced expression of Foxp3. Depletion of Tregs reversed tumor growth, and combination of Treg depletion and C3a and C5a receptor inhibition decreased tumor growth below that of the control groups. Complete knockout of C3 does not harbor the expected effect on tumor growth, indicating a still undetermined compensatory mechanism. Dexamethasone is frequently prescribed to patients undergoing RT and inhibits complement activation. We report no deleterious effects associated with dexamethasone due to complement inhibition. Conclusions: Our data establish Tregs as a pro-tumorigenic driver during complement inhibition and provide evidence that targeted C3a and C5a receptor inhibition may add therapeutic advantage when coupled with anti-Treg therapy.

16 February 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
RRRichard Blake. Ross
Richard Blake. Ross
JGJacob Gadwa
Jacob Gadwa
JYJustin Yu
Justin Yu
LDLaurel B. Darragh
Laurel B. Darragh
MKMichael W. Knitz
Michael W. Knitz
SKSana D. Karam
Sana D. Karam
Purpose: Head and neck cancer (HNC) improvements are stagnant, even with advances in immunotherapy. Our previous clinical trial data show that altered fatty acid (FA) metabolism correlates with outcome. We hypothesized that pharmacologic and dietary modulation of FA catabolism will affect therapeutic efficacy. Experimental Design: We performed in vivo and in vitro experiments using PPARα agonism with fenofibrate (FF) or high oleic acid diets (OAD) with radiotherapy, generating metabolomic, proteomic, stable isotope tracing, extracellular flux analysis, and flow-cytometric data to investigate these alterations. Results: FF improved antitumor efficacy of high dose per fraction radiotherapy in HNC murine models, whereas the OAD reversed this effect. FF-treated mice on the control diet had evidence of increased FA catabolism. Stable isotope tracing showed less glycolytic utilization by ex vivo CD8+ T cells. Improved efficacy correlated with intratumoral alterations in eicosanoid metabolism and downregulated mTOR and CD36. Conclusions: Metabolic intervention with increased FA catabolism improves the efficacy of HNC therapy and enhances antitumoral immune response.

7 January 2025 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
JGJacob Gadwa
Jacob Gadwa
JYJustin Yu
Justin Yu
MPMiles Piper
Miles Piper
MKMichael W Knitz
Michael W Knitz
LDLaurel B Darragh
Laurel B Darragh
SKSana D Karam
Sana D Karam
Background Treatment with immunotherapy can elicit varying responses across cancer types, and the mechanistic underpinnings that contribute to response vrsus progression remain poorly understood. However, to date there are few preclinical models that accurately represent these disparate disease scenarios. Methods Using combinatorial radio-immunotherapy consisting of PD-1 blockade, IL2Rβγ biased signaling, and OX40 agonism we were able to generate preclinical tumor models with conflicting responses, where head and neck squamous cell carcinoma (HNSCC) models respond and pancreatic ductal adenocarcinoma (PDAC) progresses. Results By modeling these disparate states, we find that regulatory T cells (Tregs) are expanded in PDAC tumors undergoing treatment, constraining tumor reactive CD8 T cell activity. Consequently, the depletion of Tregs restores the therapeutic efficacy of our treatment and abrogates the disparity between models. Moreover, we show that through heterotopic implantations the site of tumor development defines the response to therapy, as implantation of HNSCC tumors into the pancreas resulted in comparable levels of tumor progression. Conclusions This work highlights the complexity of combining immunotherapies within the tumor microenvironment (TME) and further defines the immune and non-immune components of the TME as an intrinsic feature of immune suppression.

2 September 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
MPMiles Piper
Miles Piper
CHChloe A. Hodgson
Chloe A. Hodgson
JGJacob Gadwa
Jacob Gadwa
MHMaureen Hoen
Maureen Hoen
MKMichael W. Knitz
Michael W. Knitz
SKSana D. Karam
Sana D. Karam
In this work, we show that the combination of radiotherapy (RT) and an IL15/IL15Rα fusion complex (IL15c) fails to confer antitumor efficacy; however, a CD8-driven antitumor immune response can be elicited with the concurrent administration of an aCD25 regulatory T cell–depleting antibody. Using IL15−/− and Rag1−/− knockout mouse models, we show that the response to RT + IL15c + aCD25 is dependent on both IL15 and cytotoxic T lymphocytes. Furthermore, despite an equivalent survival benefit following treatment with RT + IL15c + aCD25 and combination RT and PD1-IL2v, a novel immunocytokine with PD1- and IL2Rβγ-binding domains, cytotoxic T lymphocyte immunophenotyping and phosphoproteomics analysis of intracellular metabolites showed a significant upregulation of activation and functionality in CD8 T cells in the RT + PD1-IL2v regimen. Finally, we show that in the absence of functional IL15 signaling, the immunostimulatory response to RT + PD1-IL2v is significantly diminished with a concurrent lack of TCF+ CD8 T-cell generation, suggesting a necessity of IL15 for CD8 stem cells in mediating a durable response to treatment. Together, our results are illustrative of a mechanism wherein unimpeded effector T-cell activation through IL2Rβ signaling and regulatory T-cell inhibition are necessary in mediating an antitumor immune response.

23 July 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
KAKhalid N.M. Abdelazeem
Khalid N.M. Abdelazeem
DNDiemmy Nguyen
Diemmy Nguyen
SCSophia Corbo
Sophia Corbo
LDLaurel B. Darragh
Laurel B. Darragh
MMMike W. Matsumoto
Mike W. Matsumoto
SKSana D. Karam
Sana D. Karam
The EphB4-ephrinB2 signaling axis has been heavily implicated in metastasis across numerous cancer types. Our emerging understanding of the dichotomous roles that EphB4 and ephrinB2 play in head and neck squamous cell carcinoma (HNSCC) poses a significant challenge to rational drug design. We find that EphB4 knockdown in cancer cells enhances metastasis in preclinical HNSCC models by augmenting immunosuppressive cells like T regulatory cells (Tregs) within the tumor microenvironment. EphB4 inhibition in cancer cells also amplifies their ability to metastasize through increased expression of genes associated with epithelial mesenchymal transition and hallmark pathways of metastasis. In contrast, vascular ephrinB2 knockout coupled with radiation therapy (RT) enhances anti-tumor immunity, reduces Treg accumulation into the tumor, and decreases metastasis. Notably, targeting the EphB4-ephrinB2 signaling axis with the engineered EphB4 ligands EFNB2-Fc-His and Fc-TNYL-RAW-GS reduces local tumor growth and distant metastasis in a preclinical model of HNSCC. Our data suggest that targeted inhibition of vascular ephrinB2 while avoiding inhibition of EphB4 in cancer cells could be a promising strategy to mitigate HNSCC metastasis.